By Priti Krishtel, JD, Co-Founder, Co-Executive Director, I-MAK On December 7, 2020, the Kaiser Permanente Institute for Health Policy hosted the first of a 2-part virtual forum examining racial equity in the drug development system, including during initial investments and…
As drug prices continue rising unsustainably in the United States, patients and payers need to understand — and policy makers need to address — how pharmaceutical companies use patents to maintain monopolies and pricing power. Patents serve as important catalysts…
Biologics — drugs derived from living organisms that are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and some cancers — are the fastest growing component of prescription drug spending. While some of these drugs have fostered significant…
The term “pay-for-delay” refers to a tactic used by brand name drug manufacturers to delay a potential competitor from bringing a generic drug alternative to market. Usually in the form of a cash payment, pay-for-delay transactions result from a patent…
